Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Journal of Shoulder and Elbow Surgery|August 2, 2011
Retrograde nailing versus locking plate osteosynthesis of proximal humeral fractures: a biomechanical studySven-Oliver Dietz, Frank Hartmann, Thomas Schwarz, et al.
Human Gene Therapy|April 27, 2002
Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a modelBoris Kubuschok, Rudolf Schmits, Frank Hartmann, et al.
Archives of Orthopaedic and Trauma Surgery|November 26, 2009
How does spinal canal decompression and dorsal stabilization affect segmental mobility? A biomechanical studyKarl-Stefan Delank, Erol Gercek, Sebastian Kuhn, et al.
Human Gene Therapy|September 13, 2012
Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trialBoris Kubuschok, Michael Pfreundschuh, Rainer Breit, et al.
Zeitschrift Fur Orthopadie Und Unfallchirurgie|May 12, 2020
Traumatic Fractures of the Thoracic SpineUlrich J A Spiegl, Klaus John Schnake, Frank Hartmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancerBoris Kubuschok, Frank Neumann, Rainer Breit, et al.
Materials (Basel, Switzerland)|August 26, 2023
Self-Assembly of Polymer-Modified FePt Magnetic Nanoparticles and Block CopolymersFrank Hartmann, Martin Bitsch, Bart-Jan Niebuur, et al.
ACS Applied Materials & Interfaces|November 25, 2025
Structural Evolution of Printed Ternary Magnetic Hybrid Thin Films Containing Soft and Hard Magnetic Nanoparticles for Coupled CompositesChristopher R Everett, Guangjiu Pan, Manuel A Reus, et al.
Global Spine Journal|February 5, 2021
Risk Factors for Failure in Conservatively Treated Osteoporotic Vertebral Fractures: A Systematic ReviewMax J Scheyerer, Ulrich J A Spiegl, Sebastian Grueninger, et al.
Blood|July 31, 2004
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupRoswitha Forstpointner, Martin Dreyling, Roland Repp, et al.
Pageof 7